Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Abstract: The present disclosure provides a method for formulating a composition of isolated and purified microbes. The present disclosure provides methods for formulating a composition for administration to a subject in need thereof. The method can comprise obtaining a mixture that is substantially dry and comprises about 10% or less residual moisture. The mixture can comprise a population of isolated and purified microbes and a pharmaceutically acceptable carrier. The population can comprise one or more obligate anaerobes that are oxygen-stable. The methods can further comprise encapsulating said mixture in an enteric-coated capsule for delivery to said subject.

Abstract: In alternative embodiments, the invention provides formulations, pharmaceutical compositions, devices and other products of manufacture comprising a therapeutically effective mixture of an insulin and a pramlintide, and methods for making and using them.

Abstract: Provided herein are formulations containing exendins, exendin agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion.

Abstract: Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent. Additionally, methods for reducing insulin-induced weight gain are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist.

Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

Abstract: Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent.

Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided

Abstract: Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.

Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

Abstract: Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

Abstract: Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.

Abstract: Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent. Additionally, methods for reducing insulin-induce weight gain are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist.

Abstract: Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.

Abstract: Methods of improving lipid profile, including methods for lowering fasting triglyceride levels and post-prandial triglyceride excursions are disclosed comprising administering an effective amount of an amylin or amylin agonist.

Abstract: Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.